Free Trial

XBiotech Q4 2023 Earnings Report

XBiotech logo
$4.56 +0.06 (+1.33%)
(As of 12/24/2024 05:19 PM ET)

XBiotech EPS Results

Actual EPS
-$0.16
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

XBiotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

XBiotech Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Last time you’ll see this priced at $1.00 (Ad)

When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!

Click here to review Tim’s special Holiday offer before it’s too late.

XBiotech Earnings Headlines

XBiotech trading halted, news pending
Will the Nasdaq 100 crash?
In a world where some top money managers say you should “diversify” with a basket of stocks to help lower risk in your portfolio… And others say you should focus on only one ticker at a time because you can’t really keep detailed tabs on 10, 20 or more stocks at once… My #1 strategy to play the Nasdaq bull run has shown the power to provide the best of BOTH worlds at the same time. Because it harnesses ONE ticker that bottles up all the firepower of Apple, Nvidia, Tesla and more into one place… While I cannot promise future returns or against losses… This strategy targets major payouts OVERNIGHT!
XBiotech Inc.: XBiotech Pauses Rheumatology program
XBiotech Halts Rheumatology Clinical Program
Xbiotech Shares Hit 52-Week Low on Halted Rheumatology Program
See More XBiotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XBiotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XBiotech and other key companies, straight to your email.

About XBiotech

XBiotech (NASDAQ:XBIT), a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

View XBiotech Profile

More Earnings Resources from MarketBeat